Neuland Laboratories Future Growth
Future criteria checks 2/6
Neuland Laboratories wird ein jährliches Wachstum der Erträge und Einnahmen um 9.2% bzw. 9.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 9% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.6% betragen.
Key information
9.2%
Earnings growth rate
9.0%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 9.4% |
| Future return on equity | 21.6% |
| Analyst coverage | Low |
| Last updated | 10 Feb 2024 |
Recent future growth updates
Recent updates
Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17
Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Neuland Laboratories (NSE:NEULANDLAB) Has A Pretty Healthy Balance Sheet
Mar 15Can You Imagine How Elated Neuland Laboratories' (NSE:NEULANDLAB) Shareholders Feel About Its 391% Share Price Gain?
Feb 28Don't Ignore The Fact That This Insider Just Sold Some Shares In Neuland Laboratories Limited (NSE:NEULANDLAB)
Feb 12Neuland Laboratories Limited (NSE:NEULANDLAB) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 04Neuland Laboratories Limited's (NSE:NEULANDLAB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Feb 03Read This Before Selling Neuland Laboratories Limited (NSE:NEULANDLAB) Shares
Jan 18
If You Like EPS Growth Then Check Out Neuland Laboratories (NSE:NEULANDLAB) Before It's Too Late
Jan 01Is Neuland Laboratories Limited (NSE:NEULANDLAB) Popular Amongst Insiders?
Dec 14Did Business Growth Power Neuland Laboratories' (NSE:NEULANDLAB) Share Price Gain of 117%?
Nov 26These 4 Measures Indicate That Neuland Laboratories (NSE:NEULANDLAB) Is Using Debt Reasonably Well
Nov 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2026 | 19,449 | 3,873 | 3,225 | N/A | 1 |
| 3/31/2025 | 17,087 | 3,188 | 2,772 | N/A | 1 |
| 3/31/2024 | 15,930 | 3,108 | 2,418 | N/A | 1 |
| 12/31/2023 | 15,809 | 3,171 | N/A | N/A | N/A |
| 9/30/2023 | 14,574 | 2,662 | 2,444 | 3,192 | N/A |
| 6/30/2023 | 13,333 | 2,154 | N/A | N/A | N/A |
| 3/31/2023 | 11,915 | 1,635 | 1,711 | 2,372 | N/A |
| 12/31/2022 | 10,406 | 1,008 | N/A | N/A | N/A |
| 9/30/2022 | 10,078 | 831 | 341 | 1,070 | N/A |
| 6/30/2022 | 9,720 | 651 | N/A | N/A | N/A |
| 3/31/2022 | 9,517 | 638 | -373 | 604 | N/A |
| 12/31/2021 | 9,400 | 593 | N/A | N/A | N/A |
| 9/30/2021 | 9,489 | 731 | 359 | 1,437 | N/A |
| 6/30/2021 | 9,324 | 742 | N/A | N/A | N/A |
| 3/31/2021 | 9,370 | 806 | 840 | 1,894 | N/A |
| 12/31/2020 | 8,852 | 540 | N/A | N/A | N/A |
| 9/30/2020 | 8,436 | 384 | 96 | 887 | N/A |
| 6/30/2020 | 7,884 | 257 | N/A | N/A | N/A |
| 3/31/2020 | 7,640 | 162 | 85 | 573 | N/A |
| 12/31/2019 | 7,443 | 321 | N/A | N/A | N/A |
| 9/30/2019 | 7,120 | 257 | 312 | 899 | N/A |
| 6/30/2019 | 6,945 | 216 | N/A | N/A | N/A |
| 3/31/2019 | 6,675 | 164 | 68 | 699 | N/A |
| 3/31/2018 | 5,284 | 121 | -1,223 | 113 | N/A |
| 3/31/2017 | 5,789 | 469 | N/A | 387 | N/A |
| 3/31/2016 | 5,100 | 273 | N/A | 448 | N/A |
| 3/31/2015 | 4,692 | 159 | N/A | 132 | N/A |
| 3/31/2014 | 4,657 | 268 | N/A | 488 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: NEULANDLABDas prognostizierte Gewinnwachstum (9.2% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: NEULANDLABDie Erträge des Unternehmens (9.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (17.8% pro Jahr).
Hohe Wachstumserträge: NEULANDLABDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: NEULANDLABDie Einnahmen des Unternehmens (9.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (10.5% pro Jahr).
Hohe Wachstumseinnahmen: NEULANDLABDie Einnahmen des Unternehmens (9.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: NEULANDLABDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.6%)